180 related articles for article (PubMed ID: 35148777)
1. SGLT2 inhibition restrains thyroid cancer growth via G1/S phase transition arrest and apoptosis mediated by DNA damage response signaling pathways.
Wang Y; Yang L; Mao L; Zhang L; Zhu Y; Xu Y; Cheng Y; Sun R; Zhang Y; Ke J; Zhao D
Cancer Cell Int; 2022 Feb; 22(1):74. PubMed ID: 35148777
[TBL] [Abstract][Full Text] [Related]
2. Sodium-glucose co-transporter-2 (SGLT-2) inhibition reduces glucose uptake to induce breast cancer cell growth arrest through AMPK/mTOR pathway.
Zhou J; Zhu J; Yu SJ; Ma HL; Chen J; Ding XF; Chen G; Liang Y; Zhang Q
Biomed Pharmacother; 2020 Dec; 132():110821. PubMed ID: 33068934
[TBL] [Abstract][Full Text] [Related]
3. Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake.
Kaji K; Nishimura N; Seki K; Sato S; Saikawa S; Nakanishi K; Furukawa M; Kawaratani H; Kitade M; Moriya K; Namisaki T; Yoshiji H
Int J Cancer; 2018 Apr; 142(8):1712-1722. PubMed ID: 29205334
[TBL] [Abstract][Full Text] [Related]
4. The SGLT2 Inhibitor Canagliflozin Prevents Carcinogenesis in a Mouse Model of Diabetes and Non-Alcoholic Steatohepatitis-Related Hepatocarcinogenesis: Association with SGLT2 Expression in Hepatocellular Carcinoma.
Jojima T; Wakamatsu S; Kase M; Iijima T; Maejima Y; Shimomura K; Kogai T; Tomaru T; Usui I; Aso Y
Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31652578
[TBL] [Abstract][Full Text] [Related]
5. Sodium-glucose cotransporter 2 inhibitor canagliflozin attenuates lung cancer cell proliferation in vitro.
Yamamoto L; Yamashita S; Nomiyama T; Kawanami T; Hamaguchi Y; Shigeoka T; Horikawa T; Tanaka Y; Yanase T; Kawanami D; Iwasaki A
Diabetol Int; 2021 Oct; 12(4):389-398. PubMed ID: 34567921
[TBL] [Abstract][Full Text] [Related]
6. Canagliflozin Inhibits Glioblastoma Growth and Proliferation by Activating AMPK.
Shoda K; Tsuji S; Nakamura S; Egashira Y; Enomoto Y; Nakayama N; Shimazawa M; Iwama T; Hara H
Cell Mol Neurobiol; 2023 Mar; 43(2):879-892. PubMed ID: 35435536
[TBL] [Abstract][Full Text] [Related]
7. SGLT2 inhibitor promotes mitochondrial dysfunction and ER-phagy in colorectal cancer cells.
Anastasio C; Donisi I; Del Vecchio V; Colloca A; Mele L; Sardu C; Marfella R; Balestrieri ML; D'Onofrio N
Cell Mol Biol Lett; 2024 May; 29(1):80. PubMed ID: 38811901
[TBL] [Abstract][Full Text] [Related]
8. The diabetes medication Canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration.
Villani LA; Smith BK; Marcinko K; Ford RJ; Broadfield LA; Green AE; Houde VP; Muti P; Tsakiridis T; Steinberg GR
Mol Metab; 2016 Oct; 5(10):1048-1056. PubMed ID: 27689018
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the sodium-glucose co-transporter SGLT2 by canagliflozin ameliorates diet-induced obesity by increasing intra-adipose sympathetic innervation.
Yang X; Liu Q; Li Y; Ding Y; Zhao Y; Tang Q; Wu T; Chen L; Pu S; Cheng S; Zhang J; Zhang Z; Huang Y; Li R; Zhao Y; Zou M; Shi X; Jiang W; Wang R; He J
Br J Pharmacol; 2021 Apr; 178(8):1756-1771. PubMed ID: 33480065
[TBL] [Abstract][Full Text] [Related]
10. p53-dependent apoptosis is essential for the antitumor effect of paclitaxel response to DNA damage in papillary thyroid carcinoma.
Wu W; Wei T; Li Z; Zhu J
Int J Med Sci; 2021; 18(14):3197-3205. PubMed ID: 34400889
[TBL] [Abstract][Full Text] [Related]
11. Interaction of the Sodium/Glucose Cotransporter (SGLT) 2 inhibitor Canagliflozin with SGLT1 and SGLT2.
Ohgaki R; Wei L; Yamada K; Hara T; Kuriyama C; Okuda S; Ueta K; Shiotani M; Nagamori S; Kanai Y
J Pharmacol Exp Ther; 2016 Jul; 358(1):94-102. PubMed ID: 27189972
[TBL] [Abstract][Full Text] [Related]
12. Canagliflozin Inhibits Human Endothelial Cell Proliferation and Tube Formation.
Behnammanesh G; Durante ZE; Peyton KJ; Martinez-Lemus LA; Brown SM; Bender SB; Durante W
Front Pharmacol; 2019; 10():362. PubMed ID: 31057401
[TBL] [Abstract][Full Text] [Related]
13. Canagliflozin mitigates carfilzomib-induced endothelial apoptosis via an AMPK-dependent pathway.
Dabour MS; Abdelgawad IY; Grant MKO; El-Sawaf ES; Zordoky BN
Biomed Pharmacother; 2023 Aug; 164():114907. PubMed ID: 37247463
[TBL] [Abstract][Full Text] [Related]
14. Sensitization of cancer cells to paclitaxel-induced apoptosis by canagliflozin.
Huang H; Kung FL; Huang YW; Hsu CC; Guh JH; Hsu LC
Biochem Pharmacol; 2024 May; 223():116140. PubMed ID: 38513740
[TBL] [Abstract][Full Text] [Related]
15. Repurposing of nitroxoline as a potential anticancer agent against human prostate cancer: a crucial role on AMPK/mTOR signaling pathway and the interplay with Chk2 activation.
Chang WL; Hsu LC; Leu WJ; Chen CS; Guh JH
Oncotarget; 2015 Nov; 6(37):39806-20. PubMed ID: 26447757
[TBL] [Abstract][Full Text] [Related]
16. SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels.
Suga T; Kikuchi O; Kobayashi M; Matsui S; Yokota-Hashimoto H; Wada E; Kohno D; Sasaki T; Takeuchi K; Kakizaki S; Yamada M; Kitamura T
Mol Metab; 2019 Jan; 19():1-12. PubMed ID: 30416006
[TBL] [Abstract][Full Text] [Related]
17. Amelioration of diabetic nephropathy by SGLT2 inhibitors independent of its glucose-lowering effect: A possible role of SGLT2 in mesangial cells.
Maki T; Maeno S; Maeda Y; Yamato M; Sonoda N; Ogawa Y; Wakisaka M; Inoguchi T
Sci Rep; 2019 Mar; 9(1):4703. PubMed ID: 30886225
[TBL] [Abstract][Full Text] [Related]
18. Aldolase A promotes proliferation and G
Fu H; Gao H; Qi X; Zhao L; Wu D; Bai Y; Li H; Liu X; Hu J; Shao S
Cancer Commun (Lond); 2018 May; 38(1):18. PubMed ID: 29764507
[TBL] [Abstract][Full Text] [Related]
19. Model-Based Evaluation of Proximal Sodium Reabsorption Through SGLT2 in Health and Diabetes and the Effect of Inhibition With Canagliflozin.
Brady JA; Hallow KM
J Clin Pharmacol; 2018 Mar; 58(3):377-385. PubMed ID: 29144539
[TBL] [Abstract][Full Text] [Related]
20. Nelfinavir inhibits proliferation and induces DNA damage in thyroid cancer cells.
Jensen K; Bikas A; Patel A; Kushchayeva Y; Costello J; McDaniel D; Burman K; Vasko V
Endocr Relat Cancer; 2017 Mar; 24(3):147-156. PubMed ID: 28137980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]